Catalent Inc. (CTLT)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | n/a |
Market Cap | 11.52B |
Revenue (ttm) | 4.41B |
Net Income (ttm) | -411.89M |
EPS (ttm) | -2.28 |
PE Ratio (ttm) | -27.84 |
Forward PE | 33.66 |
Analyst | Hold |
Ask | n/a |
Volume | 13,674,041 |
Avg. Volume (20D) | 2,227,006 |
Open | 63.49 |
Previous Close | 63.48 |
Day's Range | 63.44 - 63.50 |
52-Week Range | 42.11 - 63.50 |
Beta | 1.16 |
About CTLT
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use...
Analyst Forecast
According to 6 analyst ratings, the average rating for CTLT stock is "Hold." The 12-month stock price forecast is $63.5, which is an increase of 0.03% from the latest price.
Next Earnings Release
Analysts project revenue of $1.10B, reflecting a 6.59% YoY growth and earnings per share of 0.11, making a -145.83% decrease YoY.
Why Price Moved
News
3 months ago · businesswire.com
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids FacilitySOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a ...